Differential Diagnosis of Cirrhosis: A Comprehensive Guide for Clinicians

Cirrhosis, the advanced stage of liver fibrosis, presents a significant diagnostic challenge due to its diverse etiologies and varied clinical manifestations. Accurate diagnosis is paramount for effective patient management and prognostication. This article provides an in-depth exploration of the differential diagnosis of cirrhosis, encompassing its pathophysiology, etiology, evaluation, and clinical considerations, crucial for healthcare professionals.

Understanding Cirrhosis: An Overview

Cirrhosis is the result of chronic liver injury, leading to the replacement of normal liver tissue with fibrosis and regenerative nodules. This architectural disruption impairs liver function and can lead to a cascade of complications. While the underlying causes of cirrhosis are numerous, the end-stage presentation can be similar, necessitating a thorough differential diagnostic approach.

Etiology of Cirrhosis: Broadening the Diagnostic Scope

Identifying the underlying cause of cirrhosis is critical for targeted treatment and management. The etiologies are broadly categorized, influencing the differential diagnosis:

• Viral Hepatitis: Hepatitis B virus (HBV), Hepatitis C virus (HCV), and Hepatitis D virus (HDV) are major global causes. Distinguishing viral cirrhosis from other causes relies on serological testing and patient history.
• Alcoholic Liver Disease (ALD): Chronic alcohol abuse is a leading cause in developed countries. ALD cirrhosis often presents with specific clinical and laboratory features.
• Nonalcoholic Steatohepatitis (NASH): Associated with metabolic syndrome, NASH is increasingly prevalent. Differential diagnosis includes other metabolic and cholestatic liver diseases.
• Autoimmune Liver Diseases: Autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) require immunological evaluation for differentiation.
• Genetic and Metabolic Disorders: Hemochromatosis, Wilson disease, and alpha-1 antitrypsin deficiency are less common but crucial to consider, especially in younger patients or those with family history.
• Vascular Causes: Budd-Chiari syndrome and cardiac cirrhosis, while less frequent, should be considered in specific clinical contexts.
• Drug-Induced Liver Injury (DILI): A wide range of medications and toxins can cause chronic liver damage. A detailed medication history is essential.
• Cryptogenic Cirrhosis: In some cases, the etiology remains unclear despite thorough investigation. Cryptogenic cirrhosis represents a diagnosis of exclusion.

Epidemiology of Cirrhosis: Contextualizing the Diagnosis

Understanding the epidemiology of cirrhosis helps contextualize the differential diagnosis. While global prevalence is estimated between 0.15% and 0.27% in the US, the prevalence of specific etiologies varies geographically and demographically. For instance, HBV and HCV are more prevalent in developing regions, while ALD and NASH are more common in developed countries. Epidemiological data aids in prioritizing likely causes based on patient demographics and risk factors.

Pathophysiology of Cirrhosis: Mechanisms and Manifestations

The pathophysiology of cirrhosis involves a complex interplay of cellular and molecular events. Chronic liver injury triggers activation of hepatic stellate cells (HSCs), which transform into myofibroblasts and deposit collagen, leading to fibrosis. Kupffer cells and hepatocytes also contribute to this process by releasing inflammatory mediators.

Portal hypertension is a major consequence of cirrhosis, arising from increased intrahepatic resistance and systemic vasodilation. This hemodynamic derangement leads to ascites, varices, and hepatorenal syndrome, influencing the clinical presentation and differential considerations. The imbalance between intrahepatic vasoconstriction (due to increased endothelin-1 and decreased nitric oxide) and splanchnic vasodilation further exacerbates portal hypertension.

Histopathological Classification: Guiding Etiological Diagnosis

Histopathology plays a crucial role in confirming cirrhosis and sometimes suggesting the underlying etiology. Cirrhosis is morphologically classified as micronodular, macronodular, or mixed.

• Micronodular Cirrhosis: Characterized by uniform nodules less than 3mm, often associated with alcohol abuse, hemochromatosis, and biliary obstruction.
• Macronodular Cirrhosis: Features irregular nodules greater than 3mm, frequently seen in viral hepatitis, alpha-1 antitrypsin deficiency, and autoimmune liver diseases.
• Mixed Cirrhosis: Combines features of both, often representing progression from micronodular to macronodular forms over time.

While morphology provides clues, etiological classification, based on the underlying cause (viral, toxic, autoimmune, cholestatic, vascular, metabolic), is more clinically relevant for differential diagnosis. Liver biopsy, the gold standard, helps assess both morphology and etiology, though sampling error is a consideration.

Clinical Presentation: Differentiating Compensated and Decompensated Cirrhosis

Cirrhosis can be clinically compensated or decompensated, significantly impacting the presenting symptoms and differential diagnosis.

• Compensated Cirrhosis: Patients are often asymptomatic, with the diagnosis made incidentally through abnormal liver function tests or imaging. Mild elevations in aminotransferases or hepatomegaly may be present. In the differential diagnosis of compensated cirrhosis, consider early stages of other liver diseases or benign conditions causing mild liver enzyme elevations.
• Decompensated Cirrhosis: Marked by complications of liver dysfunction and portal hypertension, including ascites, jaundice, hepatic encephalopathy, and variceal bleeding. Decompensation signifies a more advanced stage and narrows the differential diagnosis to advanced liver diseases.

Systemic Manifestations: Broadening the Differential

Cirrhosis affects multiple organ systems, leading to diverse clinical presentations that can overlap with other conditions, complicating the differential diagnosis.

Gastrointestinal:

• Ascites: While strongly suggestive of cirrhosis, ascites can also occur in heart failure, nephrotic syndrome, and malignancy. Differentiating ascites etiology involves fluid analysis (serum-ascites albumin gradient – SAAG).
• Variceal Bleeding: Esophageal varices are a hallmark of portal hypertension, but similar bleeding can arise from gastritis, peptic ulcers, or Mallory-Weiss tears. Endoscopy is crucial for diagnosis and management.
• Caput Medusae: Prominent abdominal veins indicate portal hypertension, but less specific and may be seen in other conditions causing abdominal venous congestion.

Hematologic:

• Anemia: Common in cirrhosis, anemia can be multifactorial (folate deficiency, hemolysis, hypersplenism). Differential diagnosis includes other causes of anemia like iron deficiency, B12 deficiency, and bone marrow disorders.
• Thrombocytopenia and Leukopenia: Hypersplenism contributes to pancytopenia in cirrhosis. Other causes of cytopenias, such as primary hematologic disorders, should be considered.
• Coagulopathy: Impaired coagulation due to reduced liver synthesis of clotting factors is characteristic of cirrhosis. Differential includes inherited coagulation disorders and disseminated intravascular coagulation (DIC).

Renal:

• Hepatorenal Syndrome (HRS): A severe complication of cirrhosis characterized by renal vasoconstriction. Differential diagnosis includes other causes of acute kidney injury in cirrhotic patients, such as dehydration, sepsis, and nephrotoxic drugs.

Pulmonary:

• Hepatopulmonary Syndrome (HPS) and Portopulmonary Hypertension (PoPH): Cirrhosis-related pulmonary complications. Differential includes primary pulmonary hypertension, COPD, and other causes of hypoxemia and pulmonary hypertension.
• Hepatic Hydrothorax: Pleural effusion in cirrhotic patients. Differential includes other causes of pleural effusion like heart failure, pneumonia, and malignancy.

Skin:

• Spider Nevi and Palmar Erythema: Suggestive of hyperestrogenemia in liver disease, but can be seen in pregnancy and other conditions.
• Jaundice: A key feature of decompensated cirrhosis, but jaundice is a broad symptom with a wide differential, including biliary obstruction (stones, malignancy), hemolytic anemia, and other liver diseases.

Endocrine:

• Hypogonadism and Gynecomastia: Common in alcoholic cirrhosis, but can also occur in other liver diseases and endocrine disorders. Differential includes primary hypogonadism and medication-induced gynecomastia.

Nail Changes:

• Clubbing, Terry’s nails, Muehrcke’s nails: Nail changes are suggestive but not specific to cirrhosis and can be seen in other systemic diseases.

Neurological:

• Hepatic Encephalopathy (HE): A neuropsychiatric complication of cirrhosis. Differential diagnosis of altered mental status in cirrhotic patients includes infections (sepsis, meningitis), electrolyte imbalances, and structural brain lesions. Asterixis and fetor hepaticus are supportive findings for HE.

Evaluation of Cirrhosis: A Step-by-Step Diagnostic Approach

The evaluation of suspected cirrhosis is multifaceted, aiming to confirm the diagnosis, determine the etiology, and assess disease severity.

Laboratory Investigations:

• Liver Function Tests (LFTs): Elevated aminotransferases (AST, ALT), alkaline phosphatase (ALP), and bilirubin are common, but normal LFTs do not exclude cirrhosis. AST/ALT ratio >1 is suggestive of alcoholic cirrhosis.
• Synthetic Function Tests: Prothrombin time (PT) prolongation and low serum albumin are direct indicators of impaired liver synthetic function and are crucial for assessing severity.
• Complete Blood Count (CBC): Anemia, thrombocytopenia, and leukopenia may be present.
• Specific Etiology-Based Tests:
  • Viral Hepatitis Serology: HBsAg, anti-HCV antibodies, HCV RNA, anti-HDV antibodies.
  • Autoimmune Markers: ANA, ASMA, anti-LKM1, serum IgG, anti-mitochondrial antibodies (AMA).
  • Metabolic Screen: Ferritin, transferrin saturation, ceruloplasmin, urinary copper, alpha-1 antitrypsin levels.
  • Alpha-fetoprotein (AFP): Elevated AFP can suggest hepatocellular carcinoma (HCC) in cirrhotic patients, aiding in differential diagnosis from benign nodules.

Imaging Modalities:

• Ultrasound: Initial imaging modality, can detect liver nodularity, increased echogenicity, and ascites. Doppler ultrasound assesses portal vein patency and flow direction, crucial for evaluating portal hypertension. Ultrasound is also used for HCC surveillance.
• CT and MRI: Superior for detecting HCC and vascular lesions. MRI is particularly useful for characterizing liver nodules and assessing iron or fat deposition. Magnetic resonance cholangiopancreatography (MRCP) can evaluate biliary obstruction.
• Transient Elastography (FibroScan): Non-invasive assessment of liver stiffness, correlating with fibrosis severity. Helps differentiate cirrhosis from earlier stages of liver disease.

Liver Biopsy:

• Gold Standard: Liver biopsy remains the gold standard for confirming cirrhosis, assessing histological features (morphology), and sometimes aiding in etiological diagnosis. It allows for grading of inflammation and staging of fibrosis. However, it is invasive and subject to sampling error.

Esophagogastroduodenoscopy (EGD):

• Variceal Screening: EGD is essential for detecting esophageal and gastric varices, complications of portal hypertension.

Differential Diagnosis of Cirrhosis: Key Considerations

The differential diagnosis of cirrhosis involves considering conditions that mimic its clinical or laboratory features. Key categories to differentiate from cirrhosis include:

1. Other Chronic Liver Diseases (Pre-cirrhotic Stages):

   • Chronic Hepatitis (Viral, Autoimmune, NASH): Differentiating early fibrosis from established cirrhosis is critical. Liver biopsy and non-invasive fibrosis assessments (FibroScan, serum markers) are helpful.
   • Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC) without Cirrhosis: Early stages may present with cholestatic LFT abnormalities but without cirrhosis. Imaging and biopsy can differentiate.
   • Hemochromatosis, Wilson Disease, Alpha-1 Antitrypsin Deficiency without Cirrhosis: Genetic and metabolic testing can identify these conditions before cirrhosis develops.

2. Conditions Mimicking Portal Hypertension:

   • Pre-hepatic Portal Hypertension: Portal vein thrombosis, splenic vein thrombosis. Doppler ultrasound and CT/MRI angiography are diagnostic.
   • Post-hepatic Portal Hypertension: Budd-Chiari syndrome, veno-occlusive disease, constrictive pericarditis, right heart failure. Imaging (Doppler ultrasound, CT/MRI, echocardiography) is crucial for differentiation.

3. Conditions Presenting with Liver Dysfunction and Jaundice:

   • Acute Liver Failure: Rapid onset of jaundice, encephalopathy, and coagulopathy. Etiologies include acute viral hepatitis, drug-induced liver injury, and autoimmune hepatitis. Clinical course and specific etiologic testing differentiate from chronic cirrhosis with decompensation.
   • Biliary Obstruction (Choledocholithiasis, Cholangitis, Pancreatic Cancer): Presents with jaundice and cholestatic LFT pattern. Imaging (ultrasound, CT, MRCP) is essential to identify biliary obstruction.

4. Systemic Diseases with Liver Involvement:

   • Cardiac Diseases (Congestive Heart Failure, Constrictive Pericarditis): Can cause “cardiac cirrhosis” or liver congestion mimicking cirrhosis. Clinical context, cardiac evaluation (echocardiography), and liver biopsy can differentiate.
   • Infiltrative Liver Diseases (Amyloidosis, Sarcoidosis, Lymphoma): Can cause hepatomegaly and abnormal LFTs. Liver biopsy is often necessary for diagnosis.

5. Acute Conditions Mimicking Decompensated Cirrhosis:

   • Acute Fatty Liver of Pregnancy (AFLP): Occurs in late pregnancy, presenting with jaundice, encephalopathy, and coagulopathy. Clinical context and rapid progression are key differentiators.
   • HELLP Syndrome (Hemolysis, Elevated Liver Enzymes, Low Platelets): Pregnancy-related condition with liver involvement. Clinical presentation and pregnancy context are differentiating factors.
   • Severe Infections (Sepsis, Viral Hemorrhagic Fevers): Systemic infections can cause liver dysfunction. Clinical context and infectious workup are crucial.
   • Toxic Ingestions (Acetaminophen Overdose, Amanita Mushroom Poisoning): History of ingestion and specific toxicological testing are important.

Differential Diagnosis Table: Key Features and Differentiators

Condition	Key Differentiating Features	Diagnostic Modalities
Chronic Hepatitis	Less advanced fibrosis, less portal hypertension, fewer decompensation signs	Liver biopsy, FibroScan, serum fibrosis markers
PBC/PSC (Early)	Cholestatic LFT pattern, autoimmune markers, no cirrhosis on imaging/biopsy (early stages)	AMA/ANCA, MRCP, liver biopsy
Pre-hepatic Portal HTN	Splenomegaly without liver dysfunction, normal LFTs, portal vein thrombosis on Doppler	Doppler ultrasound, CT/MRI angiography
Post-hepatic Portal HTN	Signs of right heart failure, Budd-Chiari on imaging	Echocardiography, Doppler ultrasound/CT/MRI of hepatic veins
Acute Liver Failure	Rapid onset, severe encephalopathy, marked coagulopathy, often identifiable acute etiology	Clinical course, acute hepatitis serology, toxicology screen
Biliary Obstruction	Marked cholestatic jaundice, dilated bile ducts on imaging	Ultrasound, CT, MRCP
Cardiac Liver Disease	Signs of heart failure, elevated JVP, echocardiography findings	Echocardiography, clinical correlation
AFLP/HELLP	Pregnancy context, specific clinical criteria	Clinical presentation, pregnancy history
Toxic Liver Injury (Acute)	History of toxin exposure, specific toxicological findings	History, toxicology screen

Prognosis and Complications: Impact of Differential Diagnosis

Accurate differential diagnosis not only guides treatment but also influences prognosis and management of complications. Predictive models like Child-Pugh and MELD scores are used to assess disease severity and predict prognosis in cirrhosis. However, prognosis varies depending on the underlying etiology and presence of complications. Liver transplantation is considered in decompensated cirrhosis unresponsive to medical therapy.

Complications of cirrhosis, including portal hypertension, ascites, variceal bleeding, hepatic encephalopathy, and HCC, require specific management strategies. Differentiating cirrhosis from mimicking conditions is essential to avoid inappropriate or delayed treatment, improving patient outcomes.

Deterrence and Patient Education: Lifestyle Modifications

While cirrhosis is irreversible, addressing the underlying etiology and implementing lifestyle modifications can slow progression and manage symptoms. Patient education is crucial, focusing on:

• Alcohol Abstinence: Essential for ALD and beneficial in all etiologies to reduce liver injury.
• Dietary Modifications: Low-sodium diet for ascites management, avoidance of raw seafood in immunocompromised patients, and balanced nutrition.
• Vaccinations: Hepatitis A and B vaccination in non-immune individuals, influenza and pneumococcal vaccination.
• Medication Adherence: Compliance with prescribed medications for underlying etiology and complications.

Enhancing Healthcare Team Outcomes: Interprofessional Approach

Optimal management of cirrhosis and its differential diagnosis requires a collaborative interprofessional team, including hepatologists, gastroenterologists, radiologists, pathologists, surgeons, and primary care physicians. Effective communication and coordinated care are essential to improve patient outcomes and quality of life in this complex condition. A systematic approach to differential diagnosis, coupled with a multidisciplinary team, is critical for navigating the complexities of cirrhosis management.

References

1.Naveau S, Perlemuter G, Balian A. [Epidemiology and natural history of cirrhosis]. Rev Prat. 2005 Sep 30;55(14):1527-32. [PubMed: 16255293]

2.Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008 Mar 08;371(9615):838-51. [PMC free article: PMC2271178] [PubMed: 18328931]

3.Scaglione S, Kliethermes S, Cao G, Shoham D, Durazo R, Luke A, Volk ML. The Epidemiology of Cirrhosis in the United States: A Population-based Study. J Clin Gastroenterol. 2015 Sep;49(8):690-6. [PubMed: 25291348]

4.Braet F, Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol. 2002 Aug 23;1(1):1. [PMC free article: PMC131011] [PubMed: 12437787]

5.Deaciuc IV, D’Souza NB, Fortunato F, Hill DB, Sarphie TG, McClain CJ. Alcohol-induced sinusoidal endothelial cell dysfunction in the mouse is associated with exacerbated liver apoptosis and can be reversed by caspase inhibition. Hepatol Res. 2001 Jan 01;19(1):85-97. [PubMed: 11137483]

6.Kolios G, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol. 2006 Dec 14;12(46):7413-20. [PMC free article: PMC4087584] [PubMed: 17167827]

7.Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005 Feb;115(2):209-18. [PMC free article: PMC546435] [PubMed: 15690074]

8.Kim MY, Baik SK, Lee SS. Hemodynamic alterations in cirrhosis and portal hypertension. Korean J Hepatol. 2010 Dec;16(4):347-52. [PMC free article: PMC3304610] [PubMed: 21415576]

9.Kim MY, Baik SK. [Hyperdynamic circulation in patients with liver cirrhosis and portal hypertension]. Korean J Gastroenterol. 2009 Sep;54(3):143-8. [PubMed: 19844149]

10.Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W., Practice Guidelines Committee of the American Association for the Study of Liver Diseases. Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007 Sep;46(3):922-38. [PubMed: 17879356]

11.Casafont Morencos F, de las Heras Castaño G, Martín Ramos L, López Arias MJ, Ledesma F, Pons Romero F. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci. 1996 Mar;41(3):552-6. [PubMed: 8617135]

12.Sheen IS, Liaw YF. The prevalence and incidence of cholecystolithiasis in patients with chronic liver diseases: a prospective study. Hepatology. 1989 Apr;9(4):538-40. [PubMed: 2925157]

13.John S, Thuluvath PJ. Hyponatremia in cirrhosis: pathophysiology and management. World J Gastroenterol. 2015 Mar 21;21(11):3197-205. [PMC free article: PMC4363748] [PubMed: 25805925]

14.Lata J. Hepatorenal syndrome. World J Gastroenterol. 2012 Sep 28;18(36):4978-84. [PMC free article: PMC3460323] [PubMed: 23049205]

15.Pirovino M, Linder R, Boss C, Köchli HP, Mahler F. Cutaneous spider nevi in liver cirrhosis: capillary microscopical and hormonal investigations. Klin Wochenschr. 1988 Apr 01;66(7):298-302. [PubMed: 3131572]

16.Green GR. Mechanism of hypogonadism in cirrhotic males. Gut. 1977 Oct;18(10):843-53. [PMC free article: PMC1411687] [PubMed: 590844]

17.Van den Velde S, Nevens F, Van Hee P, van Steenberghe D, Quirynen M. GC-MS analysis of breath odor compounds in liver patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Nov 15;875(2):344-8. [PubMed: 18938115]

18.Ellis G, Goldberg DM, Spooner RJ, Ward AM. Serum enzyme tests in diseases of the liver and biliary tree. Am J Clin Pathol. 1978 Aug;70(2):248-58. [PubMed: 696683]

19.Ballard HS. The hematological complications of alcoholism. Alcohol Health Res World. 1997;21(1):42-52. [PMC free article: PMC6826798] [PubMed: 15706762]

20.Tanaka S, Okamoto Y, Yamazaki M, Mitani N, Nakqjima Y, Fukui H. Significance of hyperglobulinemia in severe chronic liver diseases–with special reference to the correlation between serum globulin/IgG level and ICG clearance. Hepatogastroenterology. 2007 Dec;54(80):2301-5. [PubMed: 18265652]

21.Tchelepi H, Ralls PW, Radin R, Grant E. Sonography of diffuse liver disease. J Ultrasound Med. 2002 Sep;21(9):1023-32; quiz 1033-4. [PubMed: 12216750]

22.Giorgio A, Amoroso P, Lettieri G, Fico P, de Stefano G, Finelli L, Scala V, Tarantino L, Pierri P, Pesce G. Cirrhosis: value of caudate to right lobe ratio in diagnosis with US. Radiology. 1986 Nov;161(2):443-5. [PubMed: 3532188]

23.Burrel M, Llovet JM, Ayuso C, Iglesias C, Sala M, Miquel R, Caralt T, Ayuso JR, Solé M, Sanchez M, Brú C, Bruix J., Barcelona Clínic Liver Cancer Group. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology. 2003 Oct;38(4):1034-42. [PubMed: 14512891]

24.Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002 Oct;97(10):2614-8. [PubMed: 12385448]

25.Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol. 2008 Sep;32(6 Suppl 1):22-39. [PubMed: 18973844]

26.Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, Messous D, Charlotte F, Di Martino V, Benhamou Y, Poynard T. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol. 2003 Aug;39(2):222-30. [PubMed: 12873819]

27.Zeremski M, Dimova RB, Benjamin S, Makeyeva J, Yantiss RK, Gambarin-Gelwan M, Talal AH. FibroSURE as a noninvasive marker of liver fibrosis and inflammation in chronic hepatitis B. BMC Gastroenterol. 2014 Jul 03;14:118. [PMC free article: PMC4086988] [PubMed: 24990385]

28.Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010 Jan;51(1):121-9. [PMC free article: PMC2799538] [PubMed: 19827166]

29.Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, Wolfe RA, Krom R., United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003 Jan;124(1):91-6. [PubMed: 12512033]

30.Vinaixa C, Rubín A, Aguilera V, Berenguer M. Recurrence of hepatitis C after liver transplantation. Ann Gastroenterol. 2013;26(4):304-313. [PMC free article: PMC3959489] [PubMed: 24714603]

31.Hayward KL, Weersink RA. Improving Medication-Related Outcomes in Chronic Liver Disease. Hepatol Commun. 2020 Nov;4(11):1562-1577. [PMC free article: PMC7603526] [PubMed: 33163829]

32.Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013 Jul;47 Suppl(0):S2-6. [PMC free article: PMC3683119] [PubMed: 23632345]